Hepatitis B

AASLD Liver Meeting Starts this Weekend in Boston

alt

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this weekend, running through November 11 at the Hynes Convention Center in Boston. Once again, this year's meeting will highlight interferon-free direct-acting antiviral regimens for hepatitis C.

HIVandHepatitis.com will be reporting from Boston next week. Follow us on Twitter @HIVandHepatitis and find conference updates using hashtag #Liver2014.

The Liver Meeting each fall and the European Association for the Study of the Liver (EASL) International Liver Congress each spring are the premier events for presentation of the latest data on treatment for hepatitis B and C.

Soon after last year's meeting, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences' sofosbuvir (Sovaldi) and Janssen's simeprevir (Olysio). This year, the FDA has just approved a once-daily coformulation of sofosbuvir/ledipasvir (Harvoni), and a decision on AbbVie's promising 3D regimen (paritaprevir/ritonavir/ombitasvir + dasabuvir) is expected soon.

In addition to presentations on new hepatitis C therapies, the Liver Meeting will also feature news about hepatitis B, fatty liver disease, and managing advanced liver disease including cirrhosis and hepatocellular carcinoma.

The full AASLD program is available online.

11/8/14